SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalGMED - GenoMed Inc.


Previous 10 Next 10 
From: jmhollen5/5/2005 2:25:49 PM
   of 347
 
GenoMed CEO Invited to Speak at Harvard Medical School 25th Class Symposium

Contact: David Moskowitz MD GenoMed, Inc. dwmoskowitz@genomed.com tel. 314-983-9933


ST. LOUIS--(May 5, 2005)--GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol GMED) announced today that its CEO, David Moskowitz MD, has been invited to speak on Clinical Genomics at the 25th Class Symposium at Harvard Medical School on June 9, 2005 (http://134.174.17.106/alumni/program-05.pdf

Said Dr. Moskowitz, "It's a tremendous honor to be selected to speak at our 25th medical class reunion. Since publishing three years ago that angiotensin I-converting enzyme ('ACE') might be the aging gene, I've been trying hard to get the word out. Last week at 'World DNA and Genome Day' in Dalian, China, the reception was quite enthusiastic. Speaking at Harvard next month should be equally productive. I've already gotten inquiries from Harvard Medical School alumni who've seen the Class Day program. The point of my talk will be that all physicians should be practicing clinical genomics already."

Added Dr. Moskowitz, "GenoMed's primary goal right now is to educate the 80 million American Baby Boomers and their physicians, not to mention the rest of the world, that medicine has already been revolutionized. Unfortunately, an entire cohort of kidney patients is just now going on dialysis in the U.S. because their physicians didn't hear about our published results three years ago. If we'd gotten to these patients then, we could have kept them off the kidney machine now. Getting the word out to patients and their physicians in time is absolutely critical. Disease doesn't wait."

About GenoMed

GenoMed, Inc. is a Next Generation DM(TM) company whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. Disease Management (DM) is the only business in healthcare which profits by lowering healthcare costs. GenoMed uses clinical genomics to keep patients healthier and out of the hospital. A St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) first reported that GenoMed applied for patents based on its finding that the ACE gene is associated with many common diseases.


.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: jmhollen who wrote (257)5/7/2005 8:41:25 AM
From: Tadsamillionaire
   of 347
 
Dr M's Thoughts about the roomers of a Gmed buyout:

Dear ,

There's no way we'd sell out cheaply, not when each wild
card patent would be worth two years of a $3 billion a year drug. We may have the makings of 20 or 30 of these wild card patents. Do the math: $3B/yr x 2 yr/wild-card x 30 wild-card patents = $180 B.

We'd also have to retain full operational control over our Next Generation DM(tm) activities in any acquisition.

So if we get acquired, it won't be cheap. My goal remains to be huge ourselves. I just wanted people to have
some idea of the magnitude of what we might be sitting on, since (a) preventing kidney dialysis, (b) significantly delaying emphysema, (c) finding the aging gene for all vertebrate species, (d) being able to predict which Caucasians will get which of the top six solid cancers, (e)
having a potential broad-spectrum anti-viral treatment, (f) having a SNPnet which can efficiently find predisposition genes for all cancers in all ethnic groups, and (g) inventing a business model that finally makes preventive medicine profitable, have evidently not been enough to be
valued by the market at more than 6 cents a share.

All I can say is, talk about a tough audience! Enron, etc. did more than just destroy consumer confidence. Those boys destroyed trust in any company. Then again, maybe our problem is just lack of publicity. I continue to think
that 80 million Baby Boomers might appreciate knowing about (c), at the very least. Unless they still think they're going to live forever, as we
did in 1968.

Yours sincerely,
Dave Moskowitz MD
ragingbull.lycos.com

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Tadsamillionaire who wrote (258)5/7/2005 4:10:05 PM
From: jmhollen
   of 347
 
Impressive letter.............

John :-)
.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: jmhollen who wrote (259)5/26/2005 8:18:07 PM
From: Tadsamillionaire
   of 347
 
Growing concern over a persistent epidemic of bird flu across Asia is leading to urgent calls from international scientists to prepare for a global flu pandemic that could strike, by some estimates, 20% of the world's population. In a collection of articles published Thursday in the journal Nature, scientists sketch out a scenario in which a strain of bird flu, which usually would not be dangerous to people, adapts to become highly contagious and deadly to humans.

news.yahoo.com

Share RecommendKeepReplyMark as Last Read


From: Tadsamillionaire5/26/2005 8:21:00 PM
   of 347
 
Avian influenza – cumulative number of cases – update 18

19 May 2005

WHO is updating its table showing cumulative numbers of human cases of H5N1 avian influenza broken down according to phases in the outbreak, which began in December 2003. [Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO]. Numbers for Viet Nam, where the vast majority of recent cases have occurred, have been amended in line with case counts provided by the Ministry of Health during late April and May. Since the third wave of infection began in Viet Nam in mid-December 2004, 49 cases have been reported. Of these cases, 17 were fatal. The most recent case was reported to the ministry on 17 April.

WHO has asked the Ministry of Health in Viet Nam to supplement the numbers with data on individual cases. Rapid field investigation of new cases, especially when these occur in clusters, remains essential to assess possible changes in transmission patterns that could indicate improved pandemic potential of the virus.

Since January 2004, when human cases of H5N1 avian influenza were first reported in the current outbreak, 97 cases and 53 deaths have been reported in Viet Nam, Thailand and Cambodia. Viet Nam, with 76 cases and 37 deaths, has been the most severely affected country, followed by Thailand, with 17 cases and 12 deaths, and Cambodia, with 4 cases and 4 deaths.
who.int

U.S. unprepared against new flu -experts The United States still has no licensed vaccine to prevent avian flu and has nowhere near enough drugs to treat the sick if there is an epidemic, experts told Congress on Thursday.
Hospitals have too little capacity to deal with the huge numbers of people who would become sick and the U.S. Health and Human Services Department does not have a plan for dealing with an epidemic, the experts said.

"Although many levels of government are paying increased attention to the problem, the United States remains woefully unprepared for an influenza pandemic that could kill millions of Americans," said Dr. Andrew Pavia, chairman of the Infectious Disease Society of America's Pandemic Influenza Task Force.

"Clearly, we need a much larger supply of drugs and vaccine to control a flu pandemic. We need to build up U.S. manufacturing capacity so that we are not dependent on other countries to meet our needs," Pavia said in remarks prepared for a hearing of the health subcommittee of the House of Representatives' Energy and Commerce Committee.

Dr. Julie Gerberding, director of the U.S. Centers for Disease Control and Prevention, said the government was working hard to address the threat.

"CDC's influenza budget is $197 million ... a lot larger than just a few years ago," Gerberding said. "We have a lot of work to do, and that work needs to be a priority."

The H5N1 strain of avian flu has killed 37 people in Vietnam, 12 in Thailand and four in Cambodia.

It could sicken up to 20 percent of the world's population if it acquires the ability to pass easily among people, says influenza expert Dr. Albert Osterhaus of the Erasmus Medical Center in Rotterdam, Netherlands.

A pandemic could send 30 million people to the hospital and a quarter of them could die, Osterhaus and colleagues predicted in articles in Thursday's issue of the journal Nature.

Influenza causes epidemics annually and kills 36,000 Americans in a normal season. Different strains emerge almost annually, and a new one can kill many more if it is one that has not affected people in recent years.

A brand-new strain, such as H5N1, could be devastating.

"The U.S. population has no immunity and therefore no protection against this deadly virus," Pavia said.

He recommended that the United States stockpile a larger supply of antiviral drugs, especially oseltamivir, made by Switzerland's Roche under the brand name Tamiflu. Avian influenza resists older antiviral drugs, like amantadine and rimantadine, but Tamiflu can help make an infection less severe.

Although Roche has quadrupled its production capacity for Tamiflu, experts believe global stockpiles will be too small for a pandemic. The current stockpile would treat less than 2 percent of the U.S. population. Pavia's group recommends having enough on hand to treat 50 percent.

The U.S. government has also contracted with Sanofi-Aventis and Chiron Corp. to make H5N1 flu vaccines, but the contracts provide for only 2 million doses and the vaccines are still experimental.

The U.S. Government Accountability Office also criticized the U.S. lack of preparation.

Marcia Crosse, Director of Health Care for the GAO, said in prepared testimony that the United States needs to address regulatory, privacy, and procedural issues surrounding measures to control the spread of disease, especially across borders.
news.yahoo.com


Share RecommendKeepReplyMark as Last Read


From: Tadsamillionaire5/26/2005 8:25:13 PM
   of 347
 
Flu pandemic warnings escalate
By Anita Manning, USA TODAY
Growing concern over a persistent epidemic of bird flu across Asia is leading to urgent calls from international scientists to prepare for a global flu pandemic that could strike, by some estimates, 20% of the world's population. usatoday.com
Subject 52075

Share RecommendKeepReplyMark as Last Read


From: Tadsamillionaire5/26/2005 8:31:11 PM
   of 347
 
Avian flu special: Avian flu: Are we ready?
Peter Aldhous1 and Sarah Tomlin2

Peter Aldhous, chief news & features editor.
Sarah Tomlin, commentary editor.

Trouble is brewing in the East. A highly pathogenic strain of avian influenza is endemic in southeast Asia. Many millions of chickens have been culled, but there is a persistent reservoir in domesticated ducks and wild birds. The H5N1 virus isn't going to go away. And each time it emerges, people can be infected.

H5N1 first reared its head in Hong Kong and southern China in 1997, killing six. Since late 2003, it has led to the deaths of more than 50 people in Vietnam, Thailand and Cambodia.

The stage is set for the emergence of a fresh human influenza pandemic. These occur when a virus to which most people have no immunity, usually an avian strain, acquires the ability to transmit readily from person to person. H5N1 hasn't yet gained that ability — and hopefully, it will not.

But if it does, the virus could spread across the globe within months. The consequences are difficult to predict. We're unlikely to be as lucky as in 1968, when the relatively mild H3N2 virus killed some 750,000 people worldwide. But the real nightmare scenario is a re-run of the H1N1 flu pandemic of 1918, which left as many as 40 million dead. Standards of health care have improved a lot since then, which will help. But if a pandemic strain were to retain H5N1's current extreme pathogenicity, a similar toll can't be ruled out.

This week, Nature devotes its News Feature and Commentary pages to a detailed consideration of the risks posed by avian flu, and how well we are prepared to deal with it. In the pages that follow, our reporters examine nations' capacity to produce a vaccine against a pandemic strain, and the adequacy of global stockpiles of antiviral drugs. They do not paint an encouraging picture.

Repeated warnings about the international community's failure to respond to the pandemic threat have fallen on deaf ears. So in our opening News Feature, we use the benefit of fictional hindsight to throw the issues into starker relief, describing a future pandemic through the weblog of a journalist in the thick of things. This is fiction, but not fantasy — the storyline was drawn up in consultation with those who could soon be dealing with the situation for real.

In our extended Commentary section, starting on page 415, experts who are grappling with the issues tackle some hard questions. Which nations are ready, and which are not? David Ho asks if China is in a better position to cope with new microbial threats since the 2003 SARS outbreak. And Anthony Fauci outlines what US researchers are doing to develop vaccines and drugs.

Asian countries are the most immediately vulnerable. Robert Webster and Diane Hulse address the possibility of controlling flu outbreaks in these nations at source, pointing to two examples of successful intervention to wipe out the disease in poultry — in Hong Kong in 1997 and more recently in Thailand. Joining up the dots between animal and human health is also the concern of Albert Osterhaus and his colleagues. They propose a permanent global flu task force to strengthen coordination among agencies on the ground.

If we are fortunate, we may still have the time to take these messages on board. As Michael Osterholm warns in his Commentary, a flu pandemic could bring human tragedy and a global economic catastrophe. Let's hope world leaders heed the warnings.

nature.com

Share RecommendKeepReplyMark as Last Read


From: jmhollen6/7/2005 9:33:14 AM
   of 347
 
GenoMed Announces 3rd Year of its West Nile Virus Trial; Now Part of BioShield II

Contact: Paula Hempen, PhD GenoMed, Inc. tel. 314-983-9933
David Moskowitz MD GenoMed, Inc. dwmoskowitz@genomed.com

ST. LOUIS--June 7, 2005--GenoMed Inc.-- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED) a St. Louis, Missouri-based Next Generation Disease Management company, announced today that it will be conducting a clinical trial to prevent and treat West Nile virus encephalitis for the third summer in a row. The Company's approach to viral diseases was recently included in BioShield II, the landmark anti-bioterrorism bill recently introduced in the U.S. Senate by Senators Joseph Lieberman (D-CT), Orrin Hatch (R-UT), and Sam Brownback (R-KS).

A part of the bill reads:

"CHAPTER 5; REPORT AND ADMINISTRATION. SEC. 2151. REPORT TO CONGRESS. Not later than 180 days after the date of enactment of this Act, the Director of the Centers for Disease Control and Prevention, in consultation with the Assistant Secretary for Medical Readiness and Response of the Department of Homeland Security and the Director of the National Institute for Allergy and Infectious Disease of the National Institutes of Health, shall submit a report to Congress that describes alternatives to traditional vaccines and anti-viral therapeutics for viral diseases, including negative immunomodulation compounds that partially suppress a macrophage-dependent innate immune response of an individual to viral pathogens, in order to decrease morbidity and mortality from an excessive immune response."

This language exactly describes GenoMed's patent-pending method to gently suppress the innate immune response in order to treat most viral diseases in the general population.

Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, "Our record in West Nile virus currently stands at 11-3. For best results, we know to use our treatment in patients who aren't immunocompromised, and to begin treatment early."

Physicians in Utah, and Stanislaus County in California, are currently studying GenoMed's WNV protocol for use in their residents.

GenoMed's protocol was also used last summer by bird rescuers, with a 50% success rate. A second trial is planned again for this summer. Owls, hawks, and eagles have been saved using GenoMed's protocol, but so far no crows. This year's goal is to try to save crows, too.

"Horses should also benefit from our approach," Dr. Moskowitz added. "Veterinarians already use non-steroidal drugs to try to reduce the brain inflammation in horses, so our anti-inflammatory approach should make sense to them."

To enroll in GenoMed's trial, which uses already existing, safe medication present in every drug store, just go to www.genomed.com and click on the link for the West Nile virus trial.

About GenoMed

GenoMed has found what it believes to be the "master" disease gene, and has already been able to prevent kidney failure due to diabetes and hypertension in whites, blacks and Hispanics; dramatically delay the progression of terminal emphysema; and begin to see success in treating autoimmune diseases, West Nile virus encephalitis, and cancer. GenoMed has recently found several thousand genes for the top six solid cancers in Caucasians--breast, colon, lung, ovarian, pancreatic, and prostate--and is currently offering its Healthchip(r) for early diagnosis of cancer on a research basis.

Share RecommendKeepReplyMark as Last Read


From: jmhollen6/14/2005 2:34:08 PM
   of 347
 
GenoMed to be Awarded Second Patent, for Treating Acute Kidney Failure Without Dialysis

Contact: David Moskowitz MD GenoMed, Inc. tel. 314.983.9933

ST. LOUIS (June 14, 2005) - GenoMed, Inc.-- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol GMED), a St. Louis, Missouri-based biotechnology and Disease Management company, announced today that the US Patent Office has allowed claims and will be following up with an issued patent shortly on the Company's treatment to treat acute kidney failure with a drug rather than the dialysis machine.

Currently, patients with acute kidney failure are placed on the kidney machine in a hospital until their own kidney function improves. The older a person is, the less likely their kidneys are to recover, and the longer they have to stay on kidney dialysis. Acute kidney failure carries a 50% risk of dying, and involves a much longer and more expensive hospitalization.

GenoMed's treatment makes use of an already existing, generic drug. It has been used in adults, including those with hepatorenal syndrome, and newborns, with over a 70% success rate. A larger trial, for publication, is being planned.

GenoMed's treatment is ideal where access to kidney dialysis is scarce, e.g. after an earthquake, or on the battlefield, or in the Third World. First World countries interested in cutting healthcare costs and improving the atrocious mortality of acute renal failure might also be interested in the company's approach.

About GenoMed

GenoMed is a Next Generation DM™ company that translates knowledge of disease pathways into better patient outcomes so as to lower healthcare costs. GenoMed is currently marketing its patent-pending protocols for preventing chronic kidney failure due to high blood pressure or diabetes, and slowing down emphysema. The Company has recently developed a Healthchip® to predict the six most common cancers in Caucasians: breast, colon, lung, ovarian, pancreatic, and prostate. Testing is available on a research basis.

Share RecommendKeepReplyMark as Last Read


From: jmhollen6/16/2005 8:23:46 PM
   of 347
 
GenoMed Treats Its First Presumptive West Nile Virus Patient of 2005

Contact: David Moskowitz MD GenoMed, Inc. tel. 314-983-9933 dwmoskowitz@genomed.com


ST. LOUIS--June 16, 2005--GenoMed Inc.-- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED) a St. Louis, Missouri-based Next Generation Disease Management company, announced today that it has successfully treated its first patient this summer with presumed West Nile virus encephalitis.

The patient is a previously healthy 17 year old woman in Philadelphia, PA, whose parents called GenoMed yesterday from her hospital room. Their daughter had been agitated with a fever for three days. Bacterial meningitis had been ruled out by the hospital staff with a spinal tap. Her parents called GenoMed when she became delirious, and could no longer recognize them, despite being on antiviral medications. A family member had found out about GenoMed's clinical trial for West Nile virus on the Internet.

After two doses on GenoMed's protocol, 12 hours apart, the patient's mental state has improved markedly, according to her mother. She could recognize her parents, could tell her mother that she felt hot and thirsty, and has been sleeping quietly.

Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, "This patient's medical team diagnosed viral encephalitis. It will take a week or two to establish whether or not it's West Nile virus encephalitis. But since our treatment approach should work for most viruses, we could initiate treatment empirically. We're extremely gratified that her family turned to us, and even more excited that the patient has responded so quickly, as we've seen in previous summers."

The patient's doctors had told her parents to be prepared for her to remain delirious or in a coma for two to three weeks.

Physicians in Stanislaus County, California are now rushing GenoMed's WNV protocol to the local Institutional Review Board for use in their residents.

To enroll in GenoMed's trial, which uses already existing, safe medication present in every drug store and hospital, just go to www.genomed.com and click on the link for the West Nile virus trial.

About GenoMed

GenoMed has found what it believes to be the "master" disease gene, and has already been able to prevent kidney failure due to diabetes and hypertension in whites, blacks and Hispanics; dramatically delay the progression of terminal emphysema; and begin to see success in treating autoimmune diseases, West Nile virus encephalitis, and cancer. GenoMed's broad-spectrum anti-viral approach was specifically mentioned in BioShield II, recently introduced in the US Senate. GenoMed has recently found several thousand genes for the top six solid cancers in Caucasians--breast, colon, lung, ovarian, pancreatic, and prostate--and is currently offering its Healthchip(r) for early diagnosis of cancer on a research basis.

.

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10